Risk factors for hyperglycemia in COVID‐19 patients treated with remdesivir

• Egile Nagusiak: Woorim Kim (Egilea), Go Woon Lee (Egilea), Nuga Rhee (Egilea), Kyung Hyun Min (Egilea), Jun Hyeob Kim (Egilea), Jin Yeon Gil (Egilea), Song Yi Kim (Egilea), Ji Min Han (Egilea), Kyung Eun Lee (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2024-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract The primary objective of this study was to investigate the factors contributing to hyperglycemic adverse events (AEs) associated with the administration of remdesivir in hospitalized patients diagnosed with coronavirus disease 2019 (COVID‐19). Furthermore, the study aimed to develop a risk...